Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check12 days agoChange DetectedThe ARCADIA bladder cancer study record is available, describing its phase 2 trial of cabozantinib plus durvalumab, participant criteria, outcome measures, and recruiting site in Milan.SummaryDifference56%

- Check19 days agoChange DetectedThe site footer now identifies the release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check33 days agoChange DetectedA notice about NIH website changes appears above the 403 error page, and the site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1; the page otherwise remains a 403 Forbidden error page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now returns a 403 Forbidden error, replacing the previously visible trial details with an access-denied message. This blocks access to core information about the trial, including its status, eligibility, locations, and contacts.SummaryDifference20%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.